Why the study?
Does sGC stimulation with BAY 41-2272 or phosphodiesterase inhibition with pentoxifylline reduce renal fibrosis in a rat model of chronic glomerulosclerosis?
Population
Rats with anti-Thy-1-induced chronic glomerulosclerosis (cGS) as a progressive model of renal fibrosis
Comparison
BAY 41-2272 or pentoxifylline starting 1 week… vs Untreated cGS rats
Design
Preclinical, randomly assigned
Follow-up
16 weeks
Authors
Loading...
Supports sGC stimulation in experimental glomerulosclerosis; leaves open translation to human CKD.
Does sGC stimulation with BAY 41-2272 or phosphodiesterase inhibition with pentoxifylline reduce renal fibrosis in a rat model of chronic glomerulosclerosis?
Pharmacological enhancement of renal cGMP levels by sGC stimulation with BAY 41-2272 represents a potentially effective antifibrotic approach in progressive kidney disorders.
Wang et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: